Table 2.
Best model fit results- mean ± standard deviation.
| Patient no. as in8 | Pre-treatment HDV RNA | Pre-treatment HBsAg | Delay before blocking production | HBsAg Clearance rate | Drug Efficacy in Blocking HDV production | Drug Efficacy in Blocking HBsAg | Loss rate of infected cells | HBsAg production ** (IU/day) |
|---|---|---|---|---|---|---|---|---|
| V0 (log(U) /mL) | H0 (log(IU) /mL) | tb days | cH days−1 | εV | εH | δ days−1 | ||
| 1 | 5.5 ± 0.2 | 4.1 ± 0.2 | 23.2 ± 3.4 | 0.35 ± 0.057 | 0.994# | 0.999 ± 0.0001 | 0.008 ± 0.026 | 107.7 |
| 2 | 7.1 ± 0.1 | 4.2 ± 0.1 | 25.0 ± 1.1 | 0.62 ± 0.099 | 0.999# | 0.999 ± 0.0005 | 0.053 ± 0.012 | 108.2 |
| 3 | 6.0 ± 0.1 | 4.5 ± 0.1 | 19.4 ± 0.6 | 0.50 ± 0.065 | 0.998# | 0.999 ± 3e-5 | 0.090 ± 0.021 | 108.3 |
| 6 | 6.7 ± 0.2 | 4.1 ± 0.2 | 32.7 ± 1.7 | 0.57 ± 0.387 | 0.957 ± 0.025 | 0.949 ± 0.0299 | 0.051 ± 0.012 | 108.0 |
| 9* | 6.5 ± 0.1 | 4.2 ± 0.1 | 25.6 ± 9.3 | 0.08 ± 0.140 | 0.867 ± 0.147 | 0.0030@ | 0.052 ± 0.028 | 107.3 |
| 11^ | 7.0 ± 0.3 | 4.0 ± 0.3 | 8.3 ± 0.4 | 0.28 ± 0.064 | 0.999# | 0.999 ± 0.0025 | 0.074 ± 0.025 | 107.6 |
| 14 | 7.4 ± 0.1 | 4.3 ± 0.1 | 42.1 ± 1.5 | 0.79 ± 0.341 | 0.994 ± 0.003 | 0.827 ± 0.0921 | 0.029 ± 0.015 | 108.3 |
| 17 | 5.7 ± 0.4 | 4.2 ± 0.4 | 13.9 ± 3.8 | 0.46 ± 0.067 | 0.997# | 0.999 ± 0.0001 | 0.014 ± 0.030 | 108.0 |
| 24 | 6.9 ± 0.1 | 4.4 ± 0.1 | 46.9 ± 1.6 | 1.17 ± 1.045 | 0.966 ± 0.021 | 0.942 ± 0.0365 | 0.067 ± 0.016 | 108.6 |
| 26 | 6.4 ± 0.3 | 3.6 ± 0.3 | 25.8 ± 14.6 | 1.00 ± 1.122 | 0.905 ± 0.237 | 0.966 ± 0.0810 | 0.125 ± 0.062 | 107.8 |
| Median (IQR) | 6.68 (6.1–7.0) | 4.2 (4.1–4.3) | 25.3 (20.3–32.7) | 0.53 (0.38–0.79) | 0.994 (0.959–0.998) | 0.982 (0.945–0.999) | 0.052 (0.035–0.074) | 108.0 (107.7–108.3) |
*, fitted until week 13; @, Range not provided due to high uncertainty; ^, Due to fitting constraints, c was set to 0.47 days−1; #, Minimal estimate since HDV dropped below LLoQ or TND during the first phase of HDV decline; **, As described in Methods; IQR, interquartile range.